Chronic myelocytic leukemia (CML): failure to detect residual normal committed stem cells in vitro

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Philadelphia chromosome-positive chronic myeloid leukemia (Ph1-positive CML) is a clonal myeloproliferative disorder.
• Understanding the persistence of normal stem cells in CML is crucial for disease pathogenesis and treatment strategies.
• Previous studies in polycythemia vera suggested the presence of normal stem cells alongside the malignant clone.

Purpose of the Study:

• To identify and quantify normal committed stem cells (CFU-C) in patients with Ph1-positive CML.
• To differentiate between CML-derived and potentially normal stem cell populations.
• To compare stem cell persistence in CML with findings in other myeloproliferative disorders like polycythemia vera.

Main Methods:

• Analysis of granulocytic colonies cultured from bone marrow and peripheral blood of five Ph1-positive CML patients.
• Patients were heterozygous for Glucose-6-Phosphate Dehydrogenase (G-6-PD) locus.
• G-6-PD enzyme typing was used to distinguish between CML clone-derived and normal stem cell-derived colonies.

Main Results:

• Normal subjects heterozygous for G-6-PD showed approximately 50% Type-A and 50% Type-B enzyme activity in colonies.
• In contrast, only two out of 1308 colonies from CML patients exhibited Type-A G-6-PD.
• The CML clones predominantly showed Type-B G-6-PD.

Conclusions:

• The study provides minimal evidence for the persistence of normal committed stem cells in Ph1-positive CML.
• This finding contrasts with observations in polycythemia vera, suggesting differences in stem cell dynamics between these clonal disorders.
• The results support the concept of a dominant malignant clone originating from a hematopoietic stem cell in CML.